Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in KRAS- and BRAF-mutant cancer cells
- PMID: 38743809
- DOI: 10.1126/scisignal.add5073
Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in KRAS- and BRAF-mutant cancer cells
Abstract
The Ras-mitogen-activated protein kinase (MAPK) pathway is a major target for cancer treatment. To better understand the genetic pathways that modulate cancer cell sensitivity to MAPK pathway inhibitors, we performed a CRISPR knockout screen with MAPK pathway inhibitors on a colorectal cancer (CRC) cell line carrying mutant KRAS. Genetic deletion of the catalytic subunit of protein phosphatase 6 (PP6), encoded by PPP6C, rendered KRAS- and BRAF-mutant CRC and BRAF-mutant melanoma cells more resistant to these inhibitors. In the absence of MAPK pathway inhibition, PPP6C deletion in CRC cells decreased cell proliferation in two-dimensional (2D) adherent cultures but accelerated the growth of tumor spheroids in 3D culture and tumor xenografts in vivo. PPP6C deletion enhanced the activation of nuclear factor κB (NF-κB) signaling in CRC and melanoma cells and circumvented the cell cycle arrest and decreased cyclin D1 abundance induced by MAPK pathway blockade in CRC cells. Inhibiting NF-κB activity by genetic and pharmacological means restored the sensitivity of PPP6C-deficient cells to MAPK pathway inhibition in CRC and melanoma cells in vitro and in CRC cells in vivo. Furthermore, a R264 point mutation in PPP6C conferred loss of function in CRC cells, phenocopying the enhanced NF-κB activation and resistance to MAPK pathway inhibition observed for PPP6C deletion. These findings demonstrate that PP6 constrains the growth of KRAS- and BRAF-mutant cancer cells, implicates the PP6-NF-κB axis as a modulator of MAPK pathway output, and presents a rationale for cotargeting the NF-κB pathway in PPP6C-mutant cancer cells.
Similar articles
-
Clinical Development of BRAF plus MEK Inhibitor Combinations.Trends Cancer. 2020 Sep;6(9):797-810. doi: 10.1016/j.trecan.2020.05.009. Epub 2020 Jun 13. Trends Cancer. 2020. PMID: 32540454 Review.
-
LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.Oncotarget. 2017 Feb 7;8(6):9251-9266. doi: 10.18632/oncotarget.14002. Oncotarget. 2017. PMID: 27999210 Free PMC article.
-
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.Cancer Discov. 2015 Apr;5(4):358-67. doi: 10.1158/2159-8290.CD-14-1518. Epub 2015 Feb 11. Cancer Discov. 2015. PMID: 25673644 Free PMC article.
-
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.Cancer Discov. 2014 Jul;4(7):816-27. doi: 10.1158/2159-8290.CD-13-0424. Epub 2014 Apr 25. Cancer Discov. 2014. PMID: 24771846 Free PMC article.
-
BRAF as a target for cancer therapy.Anticancer Agents Med Chem. 2011 Mar;11(3):285-95. doi: 10.2174/187152011795347469. Anticancer Agents Med Chem. 2011. PMID: 21426297 Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous